Search Result

Results for "

LPA1

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Endogenous Metabolite (1) LPL Receptor (19) Phosphodiesterase (PDE) (1)
By Research Areas:	Cancer (6) Cardiovascular Disease (4) Endocrinology (1) Infection (2) Inflammation/Immunology (9) Metabolic Disease (2) Neurological Disease (3)

Inhibitors & Agonists

Antibodies

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-117959

TAK-615	LPL Receptor	Inflammation/Immunology
TAK-615 is a negative allosteric modulator (NAM) of the *LPA1* receptor for the research of pulmonary fibrosis. TAK-615 binds the LPA1 receptor with high affinity (K_d high affinity of 1.7 nM and K_d low affinity of 14.5 nM) ^[1].

HY-150204

ONO-0740556	LPL Receptor	Inflammation/Immunology
ONO-0740556 is a potent Gi-coupled human lysophosphatidic acid receptor 1 (LPA1) agonist with an EC₅₀ value of 0.26 nM ^[1].

HY-120478

ASP6432	LPL Receptor	Infection
ASP6432 is a potent and selective type 1 lysophosphatidic acid receptor (LPA1) antagonist with IC₅₀s of 11 nM and 30 nM for human LPA1 and rat LPA1, respectively ^[1].

HY-16040

AM095 free acid 5+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 (free acid) is a potent *LPA1* receptor antagonist with IC₅₀ values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.

HY-16039

AM095 5+ Cited Publications	LPL Receptor	Inflammation/Immunology
AM095 is a selective *LPA₁* receptor antagonist. The IC₅₀ for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA₁-transfected CHO cells is 0.025 and 0.023 μM, respectively.

HY-139853

BMS-986278 1 Publications Verification	LPL Receptor	Others
BMS-986278 is a potent and orally active lysophosphatidic acid receptor 1 (LPA1) antagonist, with K_bs of 6.9 nM and 4.0 nM for human and mouse LPA1, respectively. BMS-986278 can be used for the research of pulmonary fibrotic diseases ^[1].

HY-15277

AM966 Maximum Cited Publications 16 Publications Verification	LPL Receptor	Inflammation/Immunology
AM966 is a high affinity, selective, oral *LPA₁*-antagonist, inhibits LPA-stimulated intracellular calcium release (IC₅₀=17 nM).

HY-18076

LPA1 receptor antagonist 1	LPL Receptor	Infection Inflammation/Immunology
LPA1 receptor antagonist 1 is a highly selective Lysophosphatidic Acid receptor-1 *(LPA1)* antagonist with an IC₅₀ of 25 nM.

HY-138453

ACT-1016-0707 LPA1 receptor antagonist 2	LPL Receptor	Inflammation/Immunology
ACT-1016-0707 (Compound 49) is an orally active and selective *LPA1* receptor antagonist. ACT-1016-0707 can be used for the research of fibrotic diseases ^[1].

HY-167862

UCM-05194	Others	Neurological Disease
UCM-05194 is a selective LPA1 receptor agonist with activity to improve neuropathic pain. UCM-05194 is a LPA1 agonist that exhibits potent and selective properties in its pharmacologically similar properties. UCM-05194 triggers LPA1-mediated cellular effects and leads to internalization of the receptor, resulting in functional inactivation in primary sensory neurons. UCM-05194 effectively reduces pain perception in in vivo models. UCM-05194 can be used to conduct research on progressive systemic diseases ^[1].

HY-100882

ONO-7300243	LPL Receptor	Cardiovascular Disease
ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC₅₀ of 0.16 μM.

HY-117444

ONO-9780307	LPL Receptor	Cancer
ONO-9780307 is a specific synthetic *LPA1* (lysophosphatidic acid receptor 1) antagonist with an IC₅₀ value of 2.7 nM ^[1].

HY-15706

H2L 5765834	LPL Receptor	Cardiovascular Disease
H2L 5765834 is an antagonist of lysophosphatidic acid receptors LPA₁, *LPA₃, and LPA₅, with IC₅₀*s of 94, 752, and 463 nM respectively ^[1].

HY-129808

VPC12249	Others	Cardiovascular Disease Cancer
VPC12249 is a competitive dual *LPA1/LPA3* antagonist with K_i values of 137nM and 428 nM, respectively. VPC12249 inhibits calcium mobilization in HEK293T cells with a K_i value of ~130 nM. VPC12249 is promising for research of ovarian cancer and hypertensive diseases ^[1].

HY-18641

Ki16198	LPL Receptor	Cancer
Ki16198 is a potent and orally active LPA receptor antagonist, the methyl ester of Ki16425 (HY-13285). Ki16198 inhibits LPA₁ and LPA₃-induced inositol phosphate production with K_i values of 0.34 μM and 0.93 μM, respectively. Ki16198 is effective for pancreatic cancer tumorigenesis and metastasis in vivo ^[1].

HY-115450

ONO-0300302	LPL Receptor	Endocrinology Cancer
ONO-0300302 is an orally active and potent *LPA1* (lysophosphatidic acid receptor 1) antagonist, with an IC₅₀ of 0.086 μM. ONO-0300302 is a slow tight binding inhibitor, and its binding affinity increases with time, with K_d of 0.34 nM (37 °C, 2 h). ONO-0300302 can be used for benign prostatic hyperplasia (BPH) research ^[1].

HY-100619A

BMS-986020 sodium 5+ Cited Publications AM152 sodium	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) sodium is a high-affinity lysophosphatidic acid receptor 1 (LPA1) antagonist ^[1]. BMS-986020 sodium inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 sodium has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-100619

BMS-986020 5+ Cited Publications AM152	LPL Receptor	Metabolic Disease Inflammation/Immunology
BMS-986020 (AM152) is a high-affinity and selective lysophosphatidic acid receptor 1 (LPA1) antagonist ^[1]. BMS-986020 inhibits bile acid and phospholipid transporters with IC₅₀s of 4.8 µM, 6.2 µM, and 7.5 µM for BSEP, MRP4, and MDR3, respectively . BMS-986020 has the potential for the treatment of idiopathic pulmonary fibrosis (IPF) .

HY-13285

Ki16425 5+ Cited Publications Debio 0719	LPL Receptor	Neurological Disease Cancer
Ki16425 (Debio 0719) is a subtype-selective, competitive antagonist of the EDG-family receptors, *LPA1* and *LPA3* with K_is of 0.34 μM and 0.93 μM, respectively. Ki16425 (Debio 0719) reduces the *LPA*-induced activation of p42/p44 MAPK ^[1] . Ki16425 can also inhibit *LPA*-induced dephosphorylation of Yes-associated protein (YAP)/TAZ in HEK293A cells .

HY-119013

VPC32183	Endogenous Metabolite	Cardiovascular Disease
VPC32183 is a competitive antagonist of LPA1 and LPA3 receptors. The activity of VPC32183 can inhibit lipid phosphatase 1 (LPP1), thereby preventing the activation of ERK(1/2) by dioctanoic acid diglyceride (DGPP 8:0). By reducing the expression of LPP1, VPC32183 can further reduce DGPP 8:0-induced ERK(1/2) activation. The effects of VPC32183 suggest that it may have a positive regulatory function in cell signaling processes ^[1].

HY-137862

1-Oleoyl lysophosphatidic acid 1 Publications Verification 1-Oleoyl-sn-glycero-3-phosphate; 1-Oleoyl-LPA	LPL Receptor	Neurological Disease
1-Oleoyl lysophosphatidic acid (1-Oleoyl-sn-glycero-3-phosphate) is an abundant lysophosphatidic acid (LPA) species with high biological activity due to its strong affinity for the LPA receptors. 1-Oleoyl lysophosphatidic acid is commonly used in most laboratories as a reagent for LPA receptor activation ^[1]. 1-Oleoyl lysophosphatidic acid increases SRE-driven β-galactosidase activity .

HY-150614

Autotaxin-IN-6	Phosphodiesterase (PDE) LPL Receptor	Cancer
Autotaxin-IN-6 (compound 23) is a potent autotaxin (ATX) inhibitor with an IC₅₀ value of 30 nM. Autotaxin-IN-6 can reduce cell migration. Autotaxin-IN-6 can be used for researching anticancer ^[1].

Cat. No.	Compare	Product Name	Application	Reactivity

HY-P83630

	EDG2 Antibody (YA3375) Lysophosphatidic acid receptor 1; LPA receptor 1; LPA-1; Lysophosphatidic acid receptor Edg-2; LPAR1; EDG2; LPA1	WB, IHC-P, IP	Human
	EDG2 Antibody (YA3375) is a rabbit-derived non-conjugated IgG antibody (Clone NO.: YA3375), targeting EDG2, with a predicted molecular weight of 41 kDa (observed band size: 41 kDa). EDG2 Antibody (YA3375) can be used for WB, IHC-P, IP experiment in human background.

Compare Products


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.